Our results suggest that treatment with Sulanemadlin in combination with anti-PD-1 immunotherapy leads to a significantly higher influx of lymphocytes, especially CD8+ T cells, with more activated and effector cytotoxic T cells per mg tumor, correlating with an overall decreased tumor size after combination treatment compared to monotherapy. This evidence concerns the gene CD8A and neoplasm.